Strategic transactions and agreements - Ayala Pharmaceuticals - Narrative (Details) - Ayala Asset Purchase Agreement - USD ($) $ in Millions |
Dec. 31, 2025 |
Mar. 25, 2024 |
|---|---|---|
| Asset acquisitions | ||
| Development milestone amount | $ 10.0 | |
| Maximum | ||
| Asset acquisitions | ||
| Payment to be made in cash | $ 27.5 |
| X | ||||||||||
- Definition Amount of liability recognized from contingent consideration in asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of liability recognized from contingent consideration in asset acquisition, classified as current. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|